Our patents
Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia has patent protection for the treatment of a large number of different cancer forms using antibodies directed against IL1RAP. Cantargia also has a patent family covering the product candidates nadunolimab (CAN04) and CAN10, as well as several patent families covering other antibodies targeting IL1RAP. Cantargia's patent strategy is global, and covers markets deemed to be of clinical and commercial relevance for the product pipeline.
| Patent family | Patent application | Approved patents | Validity |
|---|---|---|---|
| Nadunolimab (Product) | USA | Australia, Brasil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Great Britain, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey), India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA | 2035 |
| CAN10 (Product) | Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA | USA | 2041 |
| Leukemias (Treatment) | USA | 2029 | |
| Hematological cancers (Treatment/Diagnosis) | China | Australia, Canada, China, Europe (France, Germany, Great Britain, Italy, Netherlands, Spain, Switzerland), Israel, Japan, Mexico, South Africa, USA | 2030 |
| Solid tumors (Treatment/Diagnosis) | China, Europe | Australia, Brazil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland), Japan, Mexico, South Korea, USA | 2032 |
| CAN03 (Product) | China, Europe (France, Germany, UK), Japan, USA | 2035 | |
| Anti-IL1RAP antibodies (Product) | Europe | China, Japan, USA | 2037 |
| Biepitopic antibody (Product) | USA | Europe | 2039 |
| Anti-IL1RAP antibodies (Product) | PCT | 2044 |
